Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: A prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone

Journal of Bone and Mineral Research

Volumn 16, Issue 1, 2001, Pages 104-112

  Boutsen, Y ^a   Jamart, J ^a   Esselinckx, W ^a   Devogelaer, J P ^b  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Bone mineral density; Bone remodeling; Glucocorticoids; Osteoporosis; Pamidronate

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM CARBONATE; COLLAGEN TYPE 1; GLUCOCORTICOID; OSTEOCALCIN; PAMIDRONIC ACID; PREDNISOLONE;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; BONE REMODELING; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; ENZYME ACTIVITY; FEMALE; HORMONE SUBSTITUTION; HUMAN; MALE; MENOPAUSE; OSTEOLYSIS; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0035172730     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.2001.16.1.104     Document Type: Article

References (46)

1. Glucocorticoid-induced osteoporosis: Assessment and treatment
2. A UK Consensus Group on management of glucocorticoid-induced osteoporosis: An update
3. The science and therapy of glucocorticoid-induced bone loss
4. Glucocorticoid-induced osteoporosis: Both in vivo and in vitro concentrations of glucocorticoids higher than physiological levels attenuate osteoblast differentiation
5. Apoptosis and osteoporosis
6. Steroid-induced fractures and bone loss in patients with asthma
7. Physical activity, muscle strength, and calcium intake in fracture of the proximal femur in Britain
8. Hip fractures attributable to corticosteroid use
9. Bone loss in response to long-term glucocorticoid therapy
10. Rapid loss of vertebral mineral density after renal transplantation
11. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis
12. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypro-pylidene)-1,1-bisphosphonate (APD)
13. Two-year follow-up of bisphosphonate (APD) treatment in steroid osteoporosis
14. Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: An open pilot study
15. Therapy of steroid-induced bone loss in adult asthmatics with calcium, vitamin D, and a diphosphonate
16. Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss
17. Increased bone density in patients on steroids with etidronate
18. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss
19. Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women
20. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis
21. Intravenous administration of alendronate counteracts the in vivo effects of glucocorticoids on bone remodeling
22. A double-blind placebo-controlled study to determine the effects of risedronate on bone loss in glucocorticoid-treated rheumatoid arthritis
23. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis
24. Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: A randomized trial
25. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss
26. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis
27. Effects of alendronate for two years on BMD and fractures in patients receiving glucocorticoids
28. Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation
29. 36 Month intermittent cyclical etidronate treatment in patients with established corticosteroid induced osteoporosis
30. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial
31. The role of vitamin D in corticosteroid-induced osteoporosis: A meta-analytic approach
32. Reproducibility of BMD measurements on the Hologic QDR-2000
33. A newly developed spine deformity index (SDI) to quantitate vertebral crush fractures in patients with osteoporosis
34. Longitudinal data analysis using generalized linear models
35. A computer program for regression analysis of repeated measures using generalized estimating equations
36. L'atteinte hépatique dans la pseudopolyarthrite rhizomélique
37. Markers of bone metabolism in postmenopausal women with rheumatoid arthritis
38. The effect of single oral doses of prednisone on the circadian rhythm of serum osteocalcin in normal subjects
39. Relationship of glucocorticoid dosage to serum bone GLA-protein concentration in patients with rheumatologic disorders
40. Effects of short-term treatment with prednisolone and calcitriol on bone and mineral metabolism in normal men
41. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis
42. Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides
43. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women
44. Pamidronate: A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease
45. Adverse effects of bisphosphonates
46. An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates